Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Chabannon

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Bone Marrow Transplantation|July 19, 2016
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamideA Rimondo, R Crocchiolo, J El-Cheikh, et al.
Oncogene|September 28, 2005
Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapyA Gonçalves, B Esterni, F Bertucci, et al.
Bone Marrow Transplantation|September 6, 2023
Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP)N Worel, P Ljungman, I C M Verheggen, et al.
International Journal of Oncology|July 31, 1999
Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamideC Chabannon, J L Blache, I Sielleur, et al.
Bone Marrow Transplantation|December 13, 2016
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AMLF Legrand, A-C Le Floch, A Granata, et al.
Leukemia|April 12, 2003
Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantationC Chabannon, A-G Le Corroller, F Viret, et al.
Bone Marrow Transplantation|November 10, 2015
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromesR Devillier, S Bramanti, S Fürst, et al.
Bone Marrow Transplantation|June 14, 2006
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphomaD Coso, C Sebban, O Boulat, et al.
Journal of Hematotherapy|December 1, 1996
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recoveryC Faucher, A G Le Corroller, C Chabannon, et al.
Bone Marrow Transplantation|October 18, 2016
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantationL Castagna, B Sarina, R Crocchiolo, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Bone Marrow Transplantation|July 19, 2016
The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamideA Rimondo, R Crocchiolo, J El-Cheikh, et al.
Oncogene|September 28, 2005
Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapyA Gonçalves, B Esterni, F Bertucci, et al.
Bone Marrow Transplantation|September 6, 2023
Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP)N Worel, P Ljungman, I C M Verheggen, et al.
International Journal of Oncology|July 31, 1999
Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamideC Chabannon, J L Blache, I Sielleur, et al.
Bone Marrow Transplantation|December 13, 2016
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AMLF Legrand, A-C Le Floch, A Granata, et al.
Leukemia|April 12, 2003
Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantationC Chabannon, A-G Le Corroller, F Viret, et al.
Bone Marrow Transplantation|November 10, 2015
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromesR Devillier, S Bramanti, S Fürst, et al.
Bone Marrow Transplantation|June 14, 2006
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphomaD Coso, C Sebban, O Boulat, et al.
Journal of Hematotherapy|December 1, 1996
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recoveryC Faucher, A G Le Corroller, C Chabannon, et al.
Bone Marrow Transplantation|October 18, 2016
Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantationL Castagna, B Sarina, R Crocchiolo, et al.
Pageof 14